Impact of shockwave coupling on efficacy of extracorporeal shockwave lithotripsy

PURPOSE: To evaluate the impact of a slow gated treatment rate on the efficacy of extracorporeal shockwave lithotripsy (SWL). PATIENTS AND METHODS: From August 1990 to July 2002, 40,462 SWL procedures were performed using the slow frequency electrocardiography (ECG)-gated lithotripter (82.5%) and fast frequency ECG-ungated (17.5%) modes for the Medstone STS lithotripter. Treatment characteristics, including the mode of SWL, location and size of the stone, re-treatment status, auxiliary procedures required, perioperative complications, and treatment outcomes, were recorded. The stone-free rate was reported by the treating physician on the basis of the finding of no residual stone fragments on a plain radiographic image. RESULTS: The treatment rate for the slow mode was a mean of 79.6 shocks/min, while the rate for the fast mode was 120/min. The total procedure time was 47.0 minutes for the slow mode and 40.6 minutes for the fast. The overall stone-free rate was higher for slow (66.9%) than fast (63.6%) procedures (P < 0.001). The stone-free rate for 1- to 10-mm stones was higher for the slow procedures (75.7%) than the fast procedures (70.7%; P < 0.001). Upper-ureteral stones responded better to slow treatment in terms of stone-free rate (79.5% v 72.6%; P < 0.001), re-treatment rate (6.5% v 8.0%, P = 0.05), auxiliary-procedure rate (6.1% v 8.9%; P = 0.01), and efficiency quotient (71 and 62). There was no significant difference in complication rates overall between slow and fast treatment. CONCLUSIONS: With a minimal increase in procedure time, greater efficacy can be obtained for the treatment of radiopaque stones with a slower shock-delivery rate. In particular, upper-ureteral calculi and calculi <10 mm benefit from a slower treatment rate.     

Impact of fasting on shockwave lithotripsy in renal stones: a randomized controlled trial

PURPOSE: We evaluated the impact of fasting on the effectiveness of shockwave lithotripsy (SWL) in patients with renal calculi. PATIENTS AND METHODS: The study was a randomized controlled trial for patients with renal stones. Between May 2005 and November 2006, patients (n = 97) with a single radio-opaque renal stone (7-21 mm) who were candidates for SWL were enrolled. Patients were randomized to fasting (F, n = 49) and nonfasting (NF, n = 48) groups. F group patients were asked to fast for 12 hours before SWL. Urine specific gravity (SG) was measured after fasting. All patients were monitored every 2 weeks until complete stone clearance. Treatment effectiveness was defined as complete clearance up to 3 months. RESULTS: There were 32 men in the F group and 28 men in the NF group. The mean age was 37.9 +/- 8.5 years in the F group and 39.1 +/- 7.7 years in the NF group. The mean body mass index was 22.8 +/- 2.5 and 23.1 +/- 2.6 in F and NF patients, respectively. The urine SG in the F group (1.036 +/- 0.004) was significantly higher than in the NF group (1.013 +/- 0.004; P < 0.001). At 3-month follow-up, the overall stone-free rate using SWL was 86.1% in the F group, which was higher than the rate of 72.9% in the NF group; however, the difference was not statistically significant (P = 0.16). CONCLUSION: Fasting significantly changes the urine SG but does not have a significant impact on the effectiveness of SWL for isolated renal stones.     

Comparison of three analgesic regimens for pain control during shockwave lithotripsy using Dornier Delta Compact lithotripter: a randomized clinical trial

PURPOSE: To compare the efficacy and adverse effects of oral diclofenac, topical eutectic mixture of local anesthesia (EMLA), and their combination for pain control during shockwave lithotripsy (SWL) and to investigate the need for supplemental analgesia, patient satisfaction, and overall treatment outcomes. PATIENTS AND METHODS: A series of 240 consecutive patients with urolithiasis scheduled for SWL between May 2006 and December 2006 were randomized equally into three groups that were treated as follows: group A oral (tablet) diclofenac sodium 60 minutes prior to SWL (50 mg for body weight <70 kg; 100 mg for body weight >70 kg); group B occlusive dressing of EMLA (5 g) 60 minutes prior to SWL; group C combination of oral diclofenac sodium (in the prescribed dose) and occlusive dressing of EMLA (5 g) 60 minutes prior to SWL. A visual analog scale (VAS) was used for the subjective evaluation of pain. The various parameters were recorded and analyzed statistically. RESULTS: The total number of shock waves delivered, the maximum voltage used, and SWL duration were statistically greater in group C (P < 0.0001). The VAS scores at 15, 30, 45, 60, and 120 minutes and the supplemental analgesia requirement were statistically less in group C (P < 0.0001). The stone fragmentation rate, stone-free rate at 3 months (88.75%), and modified Efficiency Quotient (0.64) were statistically greater in group C (P < 0.0001). The post-SWL auxiliary procedure rate (P < 0.0001) and Steinstrasse rate (P = 0.03) were statistically less in group C. CONCLUSIONS: The use of a combination of oral diclofenac sodium and an occlusive dressing of EMLA cream during SWL provides adequate analgesia with minimal morbidity, avoids the need for parenteral analgesics and their attendant side effects, and improves the success rate of SWL.     

人参总皂甙对肾结石体外冲击波碎石后血管活性物质的调控作用

目的探讨人参总皂甙对肾结石体外冲击波碎石（ESWL）后血管活性物质的调控作用。方法选择单侧肾盂或肾盏结石患者40例,随机分为用药组和对照组,采用水囊式JT-Ⅱ型碎石机,工作电压为10.5～12.0kV,冲击2300～2500次,用药组碎石前15min滴注人参总皂甙20g,对照组仅滴生理盐水,碎石前后测定血栓素（TXA2）、前列环素（PGI2）和内皮素-1（ET-1）。结果 ESWL后6h,TXB2在用药组（1317.6±118.7)ng/L和对照组(2476.5±132.6)ng/L达最高峰,两组比较差异有非常显著性(P<0.01);PGF1α在用药组术后24h(2243.6±212.4)ng/L达高峰,对照组术后24h(1168.6±157.4)ng/L,两组比较差异有非常显著性(P<0.01）,ET-1在术后6h达高峰,用药组(668.9±72.5)ng/L和对照组(1016.8±137.5)ng/L比较差异有非常显著性(P<0.01）。结论人参总皂甙通过调控ESWL后血管活性物质的水平达到扩张血管、疏通微循环及保护肾功能的作用。     

Experience with extracorporeal shockwave lithotripsy based on 5 years' clinical use

After 6 years of experimental research at the Departments of Urology and Surgical Research of the Ludwig-Maximilian University in Munich, extracorporeal shock-wave lithotripsy (ESWL) was introduced into clinical use in 1980. Uniquely successful and increasingly requested by stone patients, the method soon became widespread. Currently more than 70 lithotriptors are in operation worldwide and over 30,000 treatments have been carried out successfully. Clinical experience in all centers has proved the safety, reliability and reproducibility of the method. Currently, approximately 70% of nonselected stone patients are eligible to receive ESWL treatment and, when combined with endourological procedures, more than 95% of patients can benefit from this method and thus avoid open surgery.     

Efficacy of extracorporeal shockwave therapy for knee osteoarthritis: a randomized controlled trial

Background

Extracorporeal shockwave therapy (ESWT) has been widely used for pain relief and treatment of musculoskeletal disorders. We aimed to assess ESWT for knee osteoarthritis (OA) over 12 wk by comparison with placebo treatment.

Materials and methods

We randomized 70 patients to receive placebo (n = 36) or ESWT (n = 34). For ESWT, patients received 4000 pulses of shockwave at 0.25 mJ/mm² weekly for 4 wk. In the placebo group, patients received shockwave at 0 mJ/mm² in the same area. The effect on OA was assessed by pain on a visual analog scale and disability on the Lequesne index, Western Ontario and McMaster University Osteoarthritis Index, and patient perception of the clinical severity of OA. Evaluation was performed at baseline and after 1, 4, and 12 wk.

Results

We found no adverse events during and after ESWT. ESWT was more effective than placebo in reducing pain on movement at each period (P < 0.01). The mean visual analog scale score with ESWT was 3.83 at 12 wk versus 7.56 at baseline (P < 0.01). The Lequesne index and the Western Ontario and McMaster University Osteoarthritis Index score were reduced with ESWT. Moreover, patient perception of clinical severity of OA was significantly greater with ESWT than that with placebo (P < 0.01).

Conclusions

ESWT is effective in reducing pain and improving knee function, with better results than placebo during the 12-wk treatment. However, further pilot studies are needed to determine whether ESWT should be recommended at an early or later stage of OA or combined with conventional therapies.     

Double-blind randomized controlled trial assessing the safety and efficacy of intravesical agents for ureteral stent symptoms after extracorporeal shockwave lithotripsy

BACKGROUND AND PURPOSE: Ureteral stents are a significant source of pain and discomfort for many urologic patients. A novel approach to addressing this problem is the intravesical instillation of a selected pharmacologic agent after stent insertion. The purpose of this study was to assess the safety and efficacy of intravesical instillation of various agents in reducing ureteral stent-associated discomfort in patients requiring a stent after extracorporeal shockwave lithotripsy (SWL). PATIENTS AND METHODS: In this double-blind prospective trial, 42 patients were randomized to receive intravesical instillation of one of three agents (oxybutynin, alkalinized lidocaine, or ketorolac) or a control solution (0.9% sodium chloride) immediately after stent insertion at time of SWL. The four groups of patients were demographically similar. Preoperative, intraoperative, and postoperative data were collected prospectively and analyzed statistically. The primary outcome measure was reduction in ureteral stent symptoms, and the secondary outcome measure was the safety of intravesical instillation of each agent through assessment of drug-related adverse events. RESULTS: There were no intraoperative or postoperative complications, nor were there any serious side effects attributable to any of the intravesically instilled agents. There was a statistically significant decrease in stent-related discomfort at the 1-hour time point in the group of patients who received intravesical ketorolac compared with the control group. CONCLUSIONS: Intravesical instillation represents a novel approach to the problem of ureteral stent-related discomfort. From our results, ketorolac appears to be the most effective intravesical agent in reducing stent-related patient discomfort, and we have established that intravesical instillation of ketorolac is safe in humans.     

The complications of extracorporeal shockwave lithotripsy: management and prevention

Extracorporeal shockwave lithotripsy has been shown to be a safe and effective method of treating most upper urinary tract stones. Major complications, although few, include haemorrhage, septicaemia, "Steinstrasse" formation and cardiac arrhythmias. The experience from 600 consecutive cases is reviewed and methods of prevention are discussed.     

Impact of renal function on efficacy of extracorporeal shockwave lithotripsy

BACKGROUND AND PURPOSE: Adequate urine production and excretion may be important for clearance of stone fragments after extracorporeal shockwave lithotripsy (SWL). This study evaluated the impact of renal function, measured by preoperative serum creatinine concentration, on the efficacy of SWL. PATIENTS AND METHODS: From 1986 to 2001, 27,299 patients with urolithiasis were treated with Medstone STS lithotripters. Seven hundred ninety-eight of these patients (2.92%) had serum creatinine concentrations >or=2.0 mg/dL. Perioperative renal function (serum creatinine), treatment parameters, stone-free success rate (no residual fragments on plain film), and perioperative complications and procedures were recorded. RESULTS: The stone-free rate for patients with serum creatinine values from 2.0 to 2.9 mg/dL (56.69%) was significantly less than that seen in patients with a creatinine concentration <2.0 mg/dL (66.20%). The retreatment rate and secondary-procedure rate were significantly higher in patients with higher serum creatinine values (9.62% and 8.92%, respectively) than in those with serum creatinine within the normal range (6.07% and 4.27%, respectively). There was no significant difference in the stone-free rate, re-treatment rate, and secondary-procedure rate of patients with serum creatinine >or=3.0 mg/dL in comparison with patients with values <2 mg/dL. Complication rates were higher for patients with serum creatinine values >4.0 mg/dL (10.91%) than for patients with creatinine <2.0 mg/dL (2.62%). CONCLUSIONS: The efficacy of SWL is decreased in patients with serum creatinine concentrations of 2.0 to 2.9 mg/dL, and the complication rate is higher in patients with serum creatinine >4.0 mg/dL. Preoperative counseling may include a discussion of the impact of renal insufficiency on success and complication rates associated with SWL.     

Assessing the efficiency of extracorporeal shockwave lithotripsy for stones in renal units with impaired function: a prospective controlled study

The objective was to determine the efficiency of extracorporeal shockwave lithotripsy (ESWL) in clearing stones from renal units with impaired function. Thirty-five patients with poorly functioning kidneys determined by intravenous urogram and ^99mtechnetium diethylene triamine pentacetic acid renal dynamic scan underwent ESWL. Stone clearance was assessed at 3 months and compared with that in normally functioning kidneys. The study group was divided into two subgroups. Those with split glomerular filtration rate (GFR) of the concerned kidney between 10 and 20 ml/min were in group 1. Group 2 consisted of patients with split GFR between 20 and 30 ml/min. A control group (group 3) was formed from patients with urolithiasis and normally functioning kidneys. The overall retreatment rate was 84.4%. The overall stone clearance rate in the study group was 34.2% while it was 57.7% in the control group. The stone clearance rate in group 2 was 40%. The difference in stone clearance rate between the study and control groups was statistically significant (P=0.023) but that between group 2 and the control group was not (P=0.159). The incidence of steinstrasse between the study group 2 and control group was not statistically significant (P=0.408). The clearance rate for ureteral stones was comparable in all the three groups. The stone-free rate and rate of steinstrasse for renal stones in kidneys with moderately impaired function were comparable to normally functioning kidneys. However, kidneys with severely impaired function had poor results. The clearance rate for ureteral stones was not influenced by the impairment of renal function.     

Effect of pressure distribution of shockwave on renal hemorrhage after extracorporeal shockwave lithotripsy: comparison of EDAP LT-01 and Siemens Lithostar.

BACKGROUND: Renal hemorrhage is the most common adverse effect of SWL, and it has been speculated to be related to the type of lithotripter used. METHODS: We investigated the incidence of renal hemorrhage in patients with urinary stones who underwent lithotripsy using either the EDAP LT-01 or the Siemens Lithostar. In addition, we performed in vitro experiments using pressure-sensitive paper in conjunction with gelatin, agar, or porcine tissue models of renal lithotripsy. RESULTS: Thirty-one (16.6%) of 187 kidneys treated with the EDAP LT-01 and 44 (19.6%) of 225 kidneys treated with the Siemens Lithostar showed intrarenal or subcapsular hemorrhage or perinephric hematoma. In particular, the incidence of subcapsular hematoma was significantly higher in the Lithostar-treated patients (P < 0.0001). We discuss our results in light of the patterns of pressure distribution obtained from the two lithotripter units using in vitro models with colorometric, pressure-sensitive paper. CONCLUSION: It appears that the Siemens Lithostar exerts a greater pressure on the renal capsule, which may account for the higher incidence of subcapsular hematoma.     

Treatment of renal stones by extracorporeal shockwave lithotripsy: an update

AIM: Despite the extensive experience with minimal invasive stone therapy, there are still different views on the ideal management of renal stones. MATERIALS AND METHODS: Analysis of the literature includes more than 14,000 patients. We have compared these data with long-term results of two major stone centers in Germany. The results have been compared concerning the anatomical kidney situation, stone size, stone localization and observation time. RESULTS: According to the importance of residual fragments following extracorporeal shock wave lithotripsy (ESWL), we have to distinguish between clinically insignificant residual fragments and clinically significant residual fragments (CIRF). 24 months following ESWL stone passage occurs as a continuous process, and if there are no clinical symptoms, any endoscopic procedure should be considered as overtreatment. According to these results, stone-free rates of patients increase in longer follow-up periods. Newer ESWL technology has increased the percentage of CIRF. CONCLUSION: We consider ESWL in most patients with renal calculi as first-line treatment, except in patients with renal calculi bigger than 30 mm in diameter.     

Sticks and stones: use of acupuncture in extracorporeal shockwave lithotripsy

BACKGROUND AND PURPOSE: Extracorporeal shockwave lithotripsy (SWL) is an effective noninvasive, outpatient method of stone clearance. In our unit, it is performed using a combination of oral analgesia and intravenous sedation, which allows us to treat to therapeutic levels in the vast majority of our patients. However, we have encountered patients who do not tolerate various elements of the analgesia protocol and thus cannot be treated to full effect. The options for these people are currently limited to either SWL under formal sedation or epidural or general anesthetic or the use of another technique of stone clearance, such as percutaneous nephrolithotomy, which may not be as appropriate, and again necessitates an anesthetic, an inpatient stay, or both. PATIENTS AND METHODS: We describe three patients who had previously failed SWL who received acupuncture in place of standard analgesia prior to the next treatment. RESULTS: All three patients were able to tolerate the procedure better and were treated at a higher level with more shocks than in the previous session. No side effects were noted. CONCLUSIONS: We propose that acupuncture may be considered in patients unable to take standard sedoanalgesia. It is a cost-effective, safe method of inducing sedation with analgesia and had no demonstrable side effects in our series. It provides an attractive alternative to the use of general or regional anesthetics in these patients.